Michelle Zimmerman is Co-Founder and CEO of Previvor Edge, a company focused on helping individuals understand and reduce their personal cancer risk through access to clinical expertise and proactive care pathways. She has spent the past 15 years as a tech-enabled healthcare operator, building and scaling solutions that improve access, outcomes, and patient experience.
Previously, Michelle built the oncology business at genomics leader Sema4 (now GeneDx), where she helped expand access to advanced genomic insights and personalized care. That experience shaped her focus on the critical gap between risk identification and action. Today, Michelle is focused on making prevention a standard, integrated part of healthcare. Through Previvor Edge, she is mobilizing the tools, experts, and education people need to take proactive steps — shifting cancer care from reactive treatment to informed, personalized prevention.
The truth is there are ways to understand our cancer risk more precisely than we do today, and there are tools to manage it. What’s missing is awareness, access, and a system built to help us use these tools before something goes wrong.